Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for chemo- and radioresistant non-Hodgkin's lymphoma cells

被引：0
|
作者：
Roscher, M. [1 ]
Hormann, I. [1 ]
Moreno, J. [2 ]
Leib, O. [2 ]
Marx, S. [2 ]
Miltner, E. [1 ]
Friesen, C. [1 ]
机构：
[1] Univ Ulm, Inst Legal Med, D-89069 Ulm, Germany
[2] Isotope Technol Garching GmbH ITG, Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2011年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S213 / S214
页数：2
相关论文
共 50 条
  • [41] Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody
    Wiseman, GA
    White, CA
    Witzig, TE
    Gordon, LI
    Emmanouilides, C
    Raubitschek, A
    Janakiraman, N
    Gutheil, J
    Schilder, RJ
    Spies, S
    Silverman, DHS
    Grillo-López, AJ
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 3281S - 3286S
  • [42] Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody
    Wagner, HN
    Wiseman, GA
    Marcus, CS
    Nabi, HA
    Nagle, CE
    Fink-Bennett, DM
    Lamonica, DM
    Conti, PS
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (02) : 267 - 272
  • [43] Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
    Morschhauser, Franck
    Leonard, John P.
    Fayad, Luis
    Coiffier, Bertrand
    Petillon, Marie-Odile
    Coleman, Morton
    Schuster, Stephen J.
    Dyer, Martin J. S.
    Horne, Heather
    Teoh, Nick
    Wegener, William A.
    Goldenberg, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3346 - 3353
  • [44] Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody
    Postema, EJ
    Oyen, WJG
    Boerman, OC
    Corstens, FHM
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 853 - 853
  • [45] A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas
    Feugier, Pierre
    FUTURE ONCOLOGY, 2015, 11 (09) : 1327 - 1342
  • [46] Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
    Forero, A
    Weiden, PL
    Vose, JM
    Knox, SJ
    LoBuglio, AF
    Hankins, J
    Goris, ML
    Picozzi, VJ
    Axworthy, DB
    Breitz, HB
    Sims, RB
    Ghalie, RG
    Shen, S
    Meredith, RF
    BLOOD, 2004, 104 (01) : 227 - 236
  • [47] Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
    Sacchi, S
    Federico, M
    Dastoli, G
    Fiorani, C
    Vinci, G
    Clò, V
    Casolari, B
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 37 (01) : 13 - 25
  • [48] Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody
    Sharkey, Robert M.
    Karacay, Habibe
    Litwin, Samuel
    Rossi, Edmund A.
    McBride, William J.
    Chang, Chien-Hsing
    Goldenberg, David M.
    CANCER RESEARCH, 2008, 68 (13) : 5282 - 5290
  • [49] Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scidmice
    Mitchell R Smith
    Indira Joshi
    Fang Jin
    Coleman Obasaju
    BMC Cancer, 5
  • [50] Rituximab (anti-CD20 monoclonal antibody) immunotherapy in patients with B-cell non-Hodgkin's lymphoma:: highly effective treatment of residual disease
    Papajík, T
    Szotkowski, T
    Raida, L
    Hubáek, J
    Faber, E
    Hlusí, A
    Vondráková, J
    Pikalová, Z
    Jedliková, K
    Jarosová, M
    Indrák, K
    LEUKEMIA, 2001, 15 (03) : 510 - 510
12345